SCHEMBL6093333

SCHEMBL6093333

COc1ccc(CCC(C)(C(N)=O)c2ccccc2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 1/20 0.48
KDM4E B2RXH2 2/20 0.48
ATM Q13315 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
REN P00797 1/20 0.47
CTSD P07339 1/20 0.47
KMT2A Q03164 2/20 0.47
LDHA P00338 1/20 0.47
PLAAT3 P53816 1/20 0.46
PLAAT5 Q96KN8 1/20 0.46
PLAAT2 Q9NWW9 1/20 0.46
PLAAT4 Q9UL19 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501747 0.88 EDNRB (0.44) SMN1; SMN2HTTKDM4EKMT2ACYP19A1
SCHEMBL4560574 0.81 MAPT (0.52) MAPTALDH1A1HTTKMT2ACYP1A2
SCHEMBL27895994 0.78 ATM (0.53) MAPTALDH1A1KDM4EATMKMT2A
SCHEMBL27879227 0.78 ATM (0.53) MAPTALDH1A1KDM4EATMKMT2A
SCHEMBL6781362 0.76 KMT2A (0.52) MAPTALDH1A1RENCTSDKMT2A
SCHEMBL6108850 0.74 CYP19A1 (0.53) ALDH1A1HTTKDM4EATMKMT2A
SCHEMBL6791052 0.74 ATM (0.58) MAPTKDM4EATMKMT2ACYP1A2
SCHEMBL8080839 0.73 KDM4E (0.58) MAPTALDH1A1SMN1; SMN2HTTKDM4E
SCHEMBL762252 0.73 ATM (0.61) MAPTALDH1A1SMN1; SMN2KDM4EATM
SCHEMBL6142341 0.73 LDHA (0.49) MAPTALDH1A1SMN1; SMN2HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078565-B2 Benzamide derivatives as antagonists of orexin receptors SMITHKLINE BEECHAM PLC (GB) 2006-07-18 US claimed
EP-1440052-B1 BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2005-12-14 EP claimed
US-7078565-B2 Benzamide derivatives as antagonists of orexin receptors SMITHKLINE BEECHAM PLC (GB) 2006-07-18 US disclosed
EP-1440052-B1 BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2005-12-14 EP disclosed
US-20050020584-A1 Benzamide derivatives as antagonists of orexin receptors SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020584-A1 Benzamide derivatives as antagonists of orexin receptors HCRTR2, HCRTR1, OXTR MAPT 1412/4885ALDH1A1 1342/4885SMN1; SMN2 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.